CN113476476A - Medicine for treating leukoderma and its preparing process - Google Patents
Medicine for treating leukoderma and its preparing process Download PDFInfo
- Publication number
- CN113476476A CN113476476A CN202110982724.0A CN202110982724A CN113476476A CN 113476476 A CN113476476 A CN 113476476A CN 202110982724 A CN202110982724 A CN 202110982724A CN 113476476 A CN113476476 A CN 113476476A
- Authority
- CN
- China
- Prior art keywords
- parts
- treating
- medicine
- butter
- vitiligo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 79
- 238000000034 method Methods 0.000 title claims description 10
- 230000008569 process Effects 0.000 title claims description 8
- 229940079593 drug Drugs 0.000 title description 7
- 206010024380 Leukoderma Diseases 0.000 title description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 60
- 206010047642 Vitiligo Diseases 0.000 claims abstract description 54
- 235000014121 butter Nutrition 0.000 claims abstract description 46
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 28
- 238000002360 preparation method Methods 0.000 claims abstract description 23
- 201000010099 disease Diseases 0.000 claims abstract description 9
- 238000003756 stirring Methods 0.000 claims description 22
- 241000411851 herbal medicine Species 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 239000002994 raw material Substances 0.000 claims description 17
- 239000000284 extract Substances 0.000 claims description 16
- 241000830535 Ligustrum lucidum Species 0.000 claims description 15
- 235000013399 edible fruits Nutrition 0.000 claims description 15
- 239000000706 filtrate Substances 0.000 claims description 13
- 244000163122 Curcuma domestica Species 0.000 claims description 9
- 235000003392 Curcuma domestica Nutrition 0.000 claims description 9
- 241000402754 Erythranthe moschata Species 0.000 claims description 9
- 235000003373 curcuma longa Nutrition 0.000 claims description 9
- 235000013976 turmeric Nutrition 0.000 claims description 9
- 244000020518 Carthamus tinctorius Species 0.000 claims description 8
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims description 8
- 238000007873 sieving Methods 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 5
- 241000213006 Angelica dahurica Species 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000012467 final product Substances 0.000 claims 1
- 239000006049 herbal material Substances 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 238000000527 sonication Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 46
- 230000007794 irritation Effects 0.000 abstract description 4
- 238000011031 large-scale manufacturing process Methods 0.000 abstract description 3
- 238000009210 therapy by ultrasound Methods 0.000 description 13
- 241000282414 Homo sapiens Species 0.000 description 12
- 230000001976 improved effect Effects 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 210000004185 liver Anatomy 0.000 description 11
- 230000036039 immunity Effects 0.000 description 10
- 230000012010 growth Effects 0.000 description 9
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 8
- 238000009792 diffusion process Methods 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 210000002752 melanocyte Anatomy 0.000 description 8
- 230000001737 promoting effect Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 208000002193 Pain Diseases 0.000 description 7
- 230000017531 blood circulation Effects 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 229910052742 iron Inorganic materials 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- 102000003425 Tyrosinase Human genes 0.000 description 6
- 108060008724 Tyrosinase Proteins 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 239000011573 trace mineral Substances 0.000 description 6
- 235000013619 trace mineral Nutrition 0.000 description 6
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 239000010949 copper Substances 0.000 description 5
- 229910052802 copper Inorganic materials 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 230000003213 activating effect Effects 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 238000000227 grinding Methods 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 230000008099 melanin synthesis Effects 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 description 3
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 3
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 3
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 description 3
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 3
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 3
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 3
- 241000519995 Stachys sylvatica Species 0.000 description 3
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000035614 depigmentation Effects 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000003061 melanogenesis Effects 0.000 description 3
- 229940100243 oleanolic acid Drugs 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 3
- 230000002633 protecting effect Effects 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- 241001446509 Psoralea Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000005054 agglomeration Methods 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- -1 iron ions Chemical class 0.000 description 2
- 208000002741 leukoplakia Diseases 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- 235000019633 pungent taste Nutrition 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 241000125175 Angelica Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000007163 Dermatomycoses Diseases 0.000 description 1
- 206010012504 Dermatophytosis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 235000001287 Guettarda speciosa Nutrition 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 244000153234 Hibiscus abelmoschus Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 241001460074 Microsporum distortum Species 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000002920 convulsive effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 229940124644 immune regulator Drugs 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 208000013469 light sensitivity Diseases 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001722 neurochemical effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 210000004694 pigment cell Anatomy 0.000 description 1
- 229920001197 polyacetylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 210000004918 root sheath Anatomy 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/55—Glands not provided for in groups A61K35/22 - A61K35/545, e.g. thyroids, parathyroids or pineal glands
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/487—Psoralea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/638—Ligustrum, e.g. Chinese privet
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention provides a medicament for treating vitiligo diseases and a preparation process thereof, and relates to the technical field of vitiligo Chinese medicinal preparations. The medicine for treating the vitiligo comprises 5-6 parts of iron powder and 5-6 parts of butter according to the parts by weight, is externally used, and has the advantages of definite curative effect, small irritation and low side effect. The invention also relates to a preparation process of the medicament for treating the leucoderma diseases, which is simple to operate and suitable for large-scale production.
Description
Technical Field
The invention relates to the technical field of leucoderma Chinese medicinal preparations, in particular to a medicament for treating leucoderma diseases and a preparation process thereof.
Background
Vitiligo is a common acquired skin disease with depigmentation, and is also classified into 'white spot', 'white barge wind', 'leucoderma' and the like in traditional Chinese medicine, because tyrosine cannot be oxidized into dihydroxyphenylalanine, and thus melanocytes at the junction of epidermis and dermis are disordered, reduced or lost, and local or generalized depigmentation is caused. Epidemiological statistical data show that the global prevalence of the vitiligo is 0.2-1.8%, the population in China is 0.1-2%, and the population without obvious gender can be ill at any age, most commonly in children and young people.
The occurrence of vitiligo may be related to factors such as autoimmunity, oxidative stress, melanocyte self-destruction, neurochemical factors, genetics, etc., but the specific pathogenesis is still unclear. At present, Western medicine clinical treatment mainly adopts immune regulators, large-dose vitamins and other medicines, decolorization therapy, physical therapy and other modes to perform symptomatic treatment, although the short-term curative effect is obvious, hormone-dependent dermatitis and other side effects are easily caused, and certain pain is brought to patients by operation. Therefore, the development of a medicament for treating the vitiligo with small irritation is very important.
Disclosure of Invention
The invention aims to provide a medicament for treating leucoderma, which has definite external curative effect, small irritation and low side effect.
The invention also aims to provide a preparation process of the medicament for treating the vitiligo, which has simple operation and is suitable for large-scale production.
The technical problem to be solved by the invention is realized by adopting the following technical scheme.
The invention provides a medicament for treating vitiligo, which comprises 5-6 parts of iron powder and 5-6 parts of butter by weight.
The invention provides a preparation process of the medicine for treating leucoderma diseases, which comprises the following steps: adding iron powder into butter, and stirring for 20-30 min to obtain medicine for treating vitiligo.
The medicament for treating the vitiligo and the preparation process thereof provided by the embodiment of the invention at least have the following beneficial effects:
on one hand, in the medicine for treating the leucoderma provided by the embodiment of the invention, the iron element is a composition of a plurality of enzymes and immune system compounds of a human body, the butter contains necessary trace elements of iron and copper required by the human body, and the essential trace elements of iron and copper are mixed with iron powder and then coated on an affected part to promote the generation of the enzyme and cells, improve the levels of CXCL10, CXCR3 and T cell subsets of leucoderma patients, regulate the immune function of the body, promote the synthesis of melanin, inhibit the further growth and diffusion of leucoderma and enable the leucoderma to be polychromatic. The butter can promote absorption of vitamins, improve immunity, and treat vitiligo by regulating immunity. The iron powder has anti-inflammatory effect, the butter has bactericidal effect, and the combination of the two can eliminate bacteria causing leucoderma, thereby inhibiting further growth and diffusion of leukoderma.
On the other hand, the embodiment of the invention also provides a preparation process of the medicament for treating the leucoderma diseases, wherein iron powder is added into butter and stirred for 20-30 minutes in the stirring process, so that the phenomenon that the iron powder is unevenly distributed due to agglomeration can be avoided, and the curative effect of the medicament is reduced. And the iron powder can be well distributed in the butter by stirring for 20-30 minutes, so that the dispersion degree of the iron powder is improved, and the quality and the curative effect of the medicine are ensured.
Detailed Description
In order to make the objects, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below. The examples, in which specific conditions are not specified, were conducted under conventional conditions or conditions recommended by the manufacturer. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products available commercially.
It should be noted that the embodiments and features of the embodiments in the present application may be combined with each other without conflict. The present invention will be described in detail below with reference to specific examples.
The embodiment of the invention provides a medicine for treating vitiligo diseases, which comprises 5-6 parts of iron powder and 5-6 parts of butter according to parts by weight.
Iron is one of essential elements for human life maintenance, is an important component of hemoglobin, and is a pale component due to lack of ruddy luster of human skin, and is a component of many enzymes and immune system compounds in human body. The deficiency of the iron element can cause people to suffer from iron deficiency anemia, so that pigment generation has certain obstacle, the skin of a human body is pale, the appetite is poor, the immunity is reduced, and the vitiligo patients are more easily attacked by various infectious diseases. Iron powder is pungent, salty and neutral in flavor, enters heart and liver meridians, has the effects of calming liver, relieving heart, eliminating carbuncle and detoxifying, and is commonly used for treating convulsive epilepsy, mania, beriberi and heart attack, furuncle and other symptoms. Mixing with butter, and applying to affected part of vitiligo patients, supplementing sufficient iron to improve immunity of vitiligo patients and increase phagocytic function of neutrophil and phagocytic cell. And the iron ions can convert carotene into substances such as vitamin A and the like, and promote the generation of antibodies, the transportation of lipids from blood, the detoxification of drugs in liver and the like. The butter is rich in saturated fatty acid, can provide energy for organism after decomposition, and also has functions of protecting viscera and maintaining body temperature, and can promote absorption of vitamins. The butter is rich in copper, which is a trace element essential for human body, has important influence on skin, bone, viscera and brain, and can be used for improving pale and lusterless complexion.
In the medicine for treating leucoderma, the iron element is a composition of a plurality of enzymes and immune system compounds of a human body, the butter contains necessary trace elements of iron and copper required by the human body, and the butter is mixed with iron powder and then coated on an affected part to promote the generation of the enzyme and cells, improve the levels of CXCL10, CXCR3 and T cell subsets of leucoderma patients, regulate the immune function of the organism, promote the synthesis of melanin and inhibit the further growth and diffusion of leukoplakia. The butter can promote absorption of vitamins, improve immunity, and treat vitiligo by regulating immunity. The iron powder has anti-inflammatory effect, the butter has bactericidal effect, and the combination of the two can eliminate bacteria causing leucoderma, thereby inhibiting further growth and diffusion of leukoderma.
The embodiment of the invention also provides a preparation process of the medicine for treating the vitiligo, which comprises the following steps: adding iron powder into butter, and stirring for 20-30 min to obtain medicine for treating vitiligo. The iron powder is added into the butter and stirred for 20-30 minutes in the stirring process, so that the iron powder is prevented from caking to cause uneven distribution, and the curative effect of the medicine is reduced. And the iron powder can be well distributed in the butter by stirring for 20-30 minutes, so that the dispersion degree of the iron powder is improved, and the quality and the curative effect of the medicine are ensured.
In order to increase the curative effect of the medicine, the butter in the embodiment of the invention is also added with the following raw materials in parts by weight: 6-10 parts of fructus psoraleae, 3-5 parts of angelica dahurica, 5-6 parts of safflower, 3-5 parts of turmeric, 3-5 parts of glossy privet fruit and 3-4 parts of musk; the raw materials are ground and sieved, and the sieving mesh number is 100-120 meshes. Wherein Bu Gu Zhi is pungent, bitter and warm in nature and enters kidney and spleen meridians. Fructus Psoraleae has effects of warming kidney, tonifying yang, promoting inspiration, relieving asthma, warming spleen, and relieving diarrhea, and can be used for dispelling pathogenic wind and removing speckle. Vitiligo skin damage compound color depends on the enhancement of melanogenesis ability of residual epidermal melanocytes in the vitiligo region and the activation of non-functional melanocytes in hair follicle outer hair root sheaths. The medicine for accelerating melanogenesis by up-regulating tyrosinase activity can promote melanocyte division and proliferation, and improve the therapeutic effect of vitiligo. Fructus Psoraleae has effects in activating up-regulated tyrosinase activity and promoting melanocyte to synthesize melanin. Furthermore, the psoralea can be used as a medicine for enhancing the light sensitivity, and the psoralea contains light-sensitive chemical components such as psoralen and the like, so that the sensitivity of the skin to ultraviolet rays can be improved, sulfydryl compounds in the epidermis can be inhibited, the inhibition on tyrosinase can be relieved, the activity of tyrosinase can be activated, the generation and the transfer of melanin granules can be accelerated, the depigmentation lesion can be improved, and the aim of treating leucoderma can be achieved.
Bai Zhi has fragrant smell, pungent and bitter taste, warm nature, entering liver, kidney and bladder meridians. Radix Angelicae Dahuricae has effects of relieving exterior syndrome, dispelling cold, dispelling pathogenic wind, relieving pain, inducing resuscitation, eliminating dampness, relieving swelling, and expelling pus, and also has effects of removing blood stasis and stopping bleeding; it is used clinically to treat wind-cold, headache, rhinitis, gastroenteritis, menoxenia, and gynecological inflammation. The radix Angelicae Dahuricae has antipyretic, analgesic, antiinflammatory, pathogenic microorganism inhibiting, central nerve regulating, blood rheology improving, and blood sugar lowering effects. Wherein, the angelica has strong antibacterial action, has different degrees of inhibition action on escherichia coli, dysentery bacillus, typhoid bacillus, pseudomonas aeruginosa, gram-positive bacteria, human tubercle bacillus and other bacteria, and the water extract has good inhibition action on dermatophyte infection.
Safflower is pungent in flavor and warm in nature, and enters heart and liver meridians. Has the functions of promoting blood circulation to restore menstrual flow, eliminating blood stasis and relieving pain. Carthami flos contains flavone, alkaloid, polyacetylene, spermidine, sterol, lignan, and polysaccharide, and has pharmacological effects of resisting myocardial ischemia, regulating blood flow dynamics, relieving inflammation, relieving pain, resisting oxidation, and regulating immunity. Safflower not only can play a role in promoting blood circulation, but also can treat color by color, and plays a role in treating 'white' aiming at leukoderma. For the qi stagnation and blood stasis type vitiligo, the medicine can be used for promoting blood circulation, dredging collaterals, removing blood stasis and promoting tissue regeneration.
The turmeric has pungent and bitter taste and warm nature, enters spleen and liver channels, can break blood and promote qi circulation, dredge channels and relieve pain, has the effects of warming middle-jiao and dispelling cold, reducing swelling, detoxifying, resisting bacteria, activating blood and dissolving stasis, relieving itching and the like, can improve metabolic disorder, regulate functions, resists oxidation and has certain health-care function. Turmeric is commonly used for treating acne, seborrheic dermatitis, dermatophytosis and the like, and has stable curative effect and small side effect. Furthermore, the turmeric volatile oil has better fat solubility, can be well absorbed by external application, has stronger bactericidal effect, and can promote skin regeneration and accelerate the compound color of white spots.
The glossy privet fruit is sweet and bitter in taste, cold in nature, enters liver and kidney channels, and has the effect of nourishing liver and kidney. Oleanolic acid in fructus Ligustri Lucidi belongs to pentacyclic triterpene compounds, and has liver protecting effect. Furthermore, oleanolic acid can obviously inhibit the phagocytic function of a mononuclear phagocyte system and macrophages, simultaneously reduce the degeneration and necrosis speed of liver cells, relieve the inflammatory reaction of liver tissues, promote the regeneration of liver cells and accelerate the repair of necrotic liver tissues. In addition, the glossy privet fruit has the functions of obviously enhancing humoral immunity, inhibiting allergic reaction, resisting inflammation and the like. Furthermore, fructus Ligustri Lucidi has effects in activating up-regulating tyrosinase activity and promoting melanocyte to synthesize melanin, so it can be used as medicine for activating tyrosinase activity, and can accelerate melanogenesis, promote melanocyte division and proliferation, and improve vitiligo therapeutic effect.
Musk, pungent in flavor and warm in nature, enters heart and spleen meridians. Musk with pungent and fragrant flavor has strong property of dredging, has strong effects of inducing resuscitation and stopping, can promote blood stasis in blood, open the harmony of channels and collaterals, and has the effects of dysmenorrhea and relieving pain. The musk is pungent and fragrant, has good functions of promoting blood circulation, resolving masses, relieving swelling and alleviating pain. In addition, Moschus can promote percutaneous absorption of the medicine to enhance curative effect of the medicine.
The traditional Chinese medicine raw materials are ground and sieved, and the sieving mesh number is 100 plus 120 meshes. The particles with the particle size can be well mixed with the iron powder, so that the particle classification caused by too large particle difference can be avoided, and the uniformity of the medicament can be improved after the particles are mixed with butter. All the medicines are mutually compatible to prepare the liniment for external use, which not only can enhance the blood flow, improve the blood circulation of the whole body and increase the nutrition of the skin lesion part, but also can promote the growth and migration of melanin, remarkably advance the regeneration time of the initial pigment of the white spot, accelerate the generation of local pigment cells, quickly control the state of an illness and convert the state of the illness of a patient from a progressive stage to a stable stage. The medicine has the functions of diminishing inflammation and sterilizing, and can eliminate bacteria causing leucoderma when being used together, thereby inhibiting further growth and diffusion of leukoplakia. The medicine for treating the vitiligo has good curative effect, high safety and small irritation.
Further, in an embodiment of the present invention, the glossy privet fruit is pretreated, and the pretreatment includes the following steps: cleaning fructus Ligustri Lucidi, adding 25-30% yellow wine, stirring, moistening for 2-3 hr, taking out, and drying to obtain fructus Ligustri Lucidi. After the glossy privet fruit is moistened by yellow wine, the contents of oleanolic acid, hydrolyzed amino acid and trace elements dissolved out by the glossy privet fruit are higher than those of the raw product; moreover, the glossy privet fruit processed with the wine is superior to the raw product in the aspects of reducing SGPT in serum, protecting liver, increasing leucocytes, enhancing nonspecific immunity function, resisting inflammation and the like; therefore, the curative effect is better. In order to avoid the failure of effective volatile substances in the glossy privet fruit at high temperature, the temperature of the moistening in the embodiment of the invention is 50-60 ℃. The glossy privet fruit is treated under the conditions, so that the effect of nourishing liver and kidney is enhanced, the content of active ingredients of the glossy privet fruit is increased, and the curative effect of treating leucoderma is improved.
In order to remove impurities in the raw materials, effective components in the traditional Chinese medicine are extracted so as to enhance the curative effect. In the embodiment of the invention, the Chinese herbal medicine raw materials are added with water and decocted for 1-3 hours at the temperature of 80-90 ℃, filtrate is obtained by filtration, the filtrate is decompressed and concentrated until the water content is 25-30 percent to obtain extract, and the extract and iron powder are added into butter and stirred for 20-30 minutes to obtain the medicine for treating leucoderma diseases. The effective components in the Chinese herbal medicines are extracted by decocting the Chinese herbal medicines so as to remove redundant impurities, the effective components are purified so as to enhance the curative effect of the Chinese herbal medicines, the failure of the effective components caused by high-temperature damage can be avoided at the temperature, and the effective components in the Chinese herbal medicines can be extracted to the maximum extent by decocting for 1-3 hours. And then filtrate obtained by filtering is concentrated under reduced pressure, so that the content of active ingredients in unit volume can be improved, the difference between the water content and the water content of the iron powder and the butter is small, the content of the iron powder in the original medicine cannot be diluted, and the curative effect of the medicine is ensured. In detail, in order to ensure the activity between the components in the drug, the temperature for decompression and concentration is 50-70 ℃ in the embodiment of the invention.
Furthermore, in the decoction step in the embodiment of the invention, the ratio of the Chinese herbal medicine raw materials to the water is 1 (4-5). Under the feed liquid ratio, the Chinese herbal medicines can be ensured to be fully contacted with water, so that the effective components are dissolved out more quickly, the raw materials can be wasted if the feed liquid ratio is too large, and the effective components are not completely extracted if the feed liquid ratio is too small, thereby reducing the bioavailability.
In order to improve the uniformity of the extract, the iron powder and the butter in the preparation process, in the stirring step of the embodiment of the invention, the mixture of the extract, the iron powder and the butter is firstly subjected to ultrasonic treatment at the temperature of 60-70 ℃ for 10-20 minutes and then stirred. The fluidity of the butter is strong at the temperature, meanwhile, ultrasonic waves generate a large amount of micro bubbles, shock waves and micro jet flow generated when the micro bubbles explode play a good impact role in a solid-liquid system, the capability of mutual collision and aggregation among molecules is enhanced, the movement of fluid is intensified, and therefore the dispersity of the solid in the liquid is improved. And the components in the medicine can be mixed more uniformly in the ultrasonic time, so that the quality and the curative effect of the medicine are guaranteed. In detail, in the embodiment of the invention, the power of ultrasonic treatment is 60-80W. Under the ultrasonic power, the phenomenon that the purity of the medicine is affected by-products generated by heating the extracting solution due to overlarge power can be avoided, and the service life of an instrument can be prolonged.
The preparation process of the medicament for treating the leucoderma diseases is simple to operate and suitable for large-scale production, and the preparation process can uniformly disperse all components in the medicament, has higher medicament stability and improves the quality of the medicament.
The features and properties of the present invention are described in further detail below with reference to examples.
Example 1
The embodiment of the invention provides a medicine for treating vitiligo diseases, which comprises the following raw materials:
6g of iron powder and 6g of butter;
the Chinese herbal medicine composition comprises the following components: 10g of fructus psoraleae, 5g of radix angelicae, 6g of safflower, 5g of turmeric, 5g of glossy privet fruit and 4g of musk.
The embodiment of the invention provides a preparation process of the medicine for treating the vitiligo diseases, which comprises the following steps:
pretreatment: cleaning fructus Ligustri Lucidi, adding 25-30% yellow wine, stirring, moistening at 50-60 deg.C for 2-3 hr, taking out, and drying to obtain fructus Ligustri Lucidi;
grinding: the Chinese herbal medicine compositions are respectively ground and sieved, and the mesh number of the sieving is 120 meshes;
decocting: decocting fructus Ligustri Lucidi and the rest Chinese medicinal composition in water at 90 deg.C for 3 hr, filtering to obtain filtrate, and concentrating the filtrate at 70 deg.C under reduced pressure until the water content is 30% to obtain extract; wherein the material-liquid ratio of the Chinese herbal medicine raw materials to the water is 1: 5;
ultrasonic treatment: carrying out ultrasonic treatment on the mixture of the extract, the iron powder and the butter at the temperature of 70 ℃ for 20 minutes, wherein the power of the ultrasonic treatment is 80W;
mixing: the medicine for treating the vitiligo diseases can be obtained by stirring the substances for 30 minutes.
Example 2
The embodiment of the invention provides a medicine for treating vitiligo diseases, which comprises the following raw materials:
5g of iron powder and 5g of butter;
the Chinese herbal medicine composition comprises the following components: 6g of fructus psoraleae, 3g of radix angelicae, 5g of safflower, 3g of turmeric, 3g of glossy privet fruit and 3g of musk.
The embodiment of the invention provides a preparation process of the medicine for treating the vitiligo diseases, which comprises the following steps:
pretreatment: adding cleaned fructus Ligustri Lucidi into 25% yellow wine, stirring, moistening at 50 deg.C for 2 hr, taking out, and drying to obtain fructus Ligustri Lucidi;
grinding: the Chinese herbal medicine compositions are respectively ground and sieved, and the sieving mesh number is 100 meshes;
decocting: decocting the fructus Ligustri Lucidi and the rest Chinese medicinal composition in water at 80 deg.C for 1 hr, filtering to obtain filtrate, and concentrating the filtrate at 50 deg.C under reduced pressure until the water content is 25% to obtain extract; wherein the material-liquid ratio of the Chinese herbal medicine raw materials to the water is 1: 4;
ultrasonic treatment: carrying out ultrasonic treatment on the mixture of the extract, the iron powder and the butter at the temperature of 60 ℃ for 10 minutes, wherein the power of the ultrasonic treatment is 60W;
mixing: the medicine for treating the vitiligo diseases can be obtained by stirring the substances for 20 minutes.
Example 3
The embodiment of the invention provides a medicine for treating vitiligo diseases, which comprises the following raw materials:
iron powder 5.5g and butter 5.5 g;
the Chinese herbal medicine composition comprises the following components: 7g of fructus psoraleae, 4g of angelica dahurica, 5.5g of safflower, 4.5g of turmeric, 4g of glossy privet fruit and 3.5g of musk.
The embodiment of the invention provides a preparation process of the medicine for treating the vitiligo diseases, which comprises the following steps:
pretreatment: adding cleaned fructus Ligustri Lucidi into 28% yellow wine, stirring, moistening at 55 deg.C for 2.5 hr, taking out, and drying to obtain fructus Ligustri Lucidi;
grinding: the Chinese herbal medicine compositions are respectively ground and sieved, and the sieving mesh number is 110 meshes;
decocting: decocting fructus Ligustri Lucidi and the rest Chinese medicinal composition in water at 85 deg.C for 2 hr, filtering to obtain filtrate, and concentrating the filtrate at 60 deg.C under reduced pressure until the water content is 28% to obtain extract;
ultrasonic treatment: carrying out ultrasonic treatment on the mixture of the extract, the iron powder and the butter at the temperature of 65 ℃ for 15 minutes, wherein the power of the ultrasonic treatment is 70W;
mixing: the medicine for treating the vitiligo diseases can be obtained by stirring the substances for 25 minutes.
Example 4
The embodiment of the invention provides a medicine for treating vitiligo diseases, which comprises the following raw materials:
iron powder 5.8g and butter 5.6 g;
the Chinese herbal medicine composition comprises the following components: 7.7g of fructus psoraleae, 4.5g of angelica dahurica, 5.2g of safflower, 3.5g of turmeric, 3.8g of glossy privet fruit and 3.5g of musk.
The embodiment of the invention provides a preparation process of the medicine for treating the vitiligo diseases, which comprises the following steps:
grinding: the Chinese herbal medicine compositions are respectively ground and sieved, and the sieving mesh number is 105 meshes;
decocting: decocting fructus Ligustri Lucidi and the rest Chinese medicinal composition in water at 83 deg.C for 1.5 hr, filtering to obtain filtrate, and concentrating the filtrate under reduced pressure until the water content is 26% to obtain extract; wherein the feed-liquid ratio of the Chinese herbal medicine raw materials to the water is 1: 4.3;
ultrasonic treatment: carrying out ultrasonic treatment on the mixture of the extract, the iron powder and the butter at the temperature of 68 ℃ for 18 minutes;
mixing: the medicine for treating the leucoderma diseases can be obtained by stirring the substances for 28 minutes.
Example 5
The embodiment of the invention provides a medicine for treating vitiligo diseases, which comprises raw materials of 5.8g of iron powder and 5.8g of butter.
The embodiment of the invention provides a preparation process of the medicine for treating the vitiligo diseases, which comprises the following steps:
the medicine for treating the vitiligo diseases can be obtained by stirring the substances for 26 minutes.
Examples of effects
The treatment method comprises the following steps: the ointment prepared by the preparation process of the medicament for treating the vitiligo diseases provided by the embodiment 1 to 5 is smeared on the spots 3 times a day, and the effect of the ointment on the color recovery of the spots is observed.
The therapeutic effect judgment standard is as follows: the curative effect is judged according to the guiding principle of clinical research of new traditional Chinese medicines. And (3) healing: the signs of symptoms disappear or substantially disappear. The effect is shown: the symptoms and physical signs are obviously improved. The method has the following advantages: the symptoms and physical signs are all improved. And (4) invalidation: the symptoms and signs are not obviously improved or even aggravated. 30 patients with vitiligo were recruited, treated with salve and recorded 3 days before and after treatment as shown in table 1.
TABLE 1 treatment before and after treatment
As can be seen from the data in table 1, the ointment of examples 1 to 5 has a significant effect on treating vitiligo diseases, which indicates that the drug for treating vitiligo diseases provided by the present invention can promote melanin synthesis, inhibit further growth and diffusion of vitiligo, and enable the vitiligo to be discolored.
In summary, the embodiments of the present invention provide a medicine for treating vitiligo, the iron element in the medicine is a composition of many enzymes and immune system compounds of human body, the butter contains necessary trace elements of iron and copper required by human body, and the butter is mixed with iron powder and then coated on the affected part to promote the generation of enzyme and cells, improve the levels of CXCL10, CXCR3 and T cell subset of vitiligo patients, regulate the immune function of the body, promote the synthesis of melanin, inhibit the further growth and diffusion of vitiligo, and enable the vitiligo to be polychromatic. The butter can promote absorption of vitamins, improve immunity, and treat vitiligo by regulating immunity. The iron powder has anti-inflammatory effect, the butter has bactericidal effect, and the combination of the two can eliminate bacteria causing leucoderma, thereby inhibiting further growth and diffusion of leukoderma.
On the other hand, the embodiment of the invention also provides a preparation process of the medicament for treating the leucoderma diseases, wherein iron powder is added into butter and stirred for 20-30 minutes in the stirring process, so that the phenomenon that the iron powder is unevenly distributed due to agglomeration can be avoided, and the curative effect of the medicament is reduced. And the iron powder can be well distributed in the butter by stirring for 20-30 minutes, so that the dispersion degree of the iron powder is improved, and the quality and the curative effect of the medicine are ensured.
The embodiments described above are some, but not all embodiments of the invention. The detailed description of the embodiments of the present invention is not intended to limit the scope of the invention as claimed, but is merely representative of selected embodiments of the invention. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Claims (10)
1. The medicine for treating leucoderma is characterized by comprising 5-6 parts of iron powder and 5-6 parts of butter according to parts by weight.
2. A process for preparing a medicament according to claim 1 for the treatment of vitiligo comprising the steps of:
adding the iron powder into the butter and stirring for 20-30 minutes to obtain the medicament for treating the leucoderma diseases.
3. The preparation process according to claim 2, wherein the following Chinese herbal medicine raw materials in parts by weight are also added into the butter:
6-10 parts of fructus psoraleae, 3-5 parts of angelica dahurica, 5-6 parts of safflower, 3-5 parts of turmeric, 3-5 parts of glossy privet fruit and 3-4 parts of musk; the Chinese herbal medicine raw materials are ground and sieved, and the sieving mesh number is 100-120 meshes.
4. The medicament for treating vitiligo according to claim 3, wherein the fructus Ligustri Lucidi is pretreated, the pretreatment comprising the steps of: adding cleaned fructus Ligustri Lucidi into 25-30% yellow wine, stirring, moistening for 2-3 hr, taking out, and drying to obtain the final product.
5. The process for preparing the medicine for treating vitiligo according to claim 4, wherein the temperature of moistening is 50-60 ℃.
6. The preparation process of claim 3, wherein the Chinese herbal materials are decocted with water at 80-90 ℃ for 1-3 hours, filtered to obtain filtrate, the filtrate is concentrated under reduced pressure until the water content is 25-30% to obtain extract, and the extract and the iron powder are added into the butter and stirred for 20-30 minutes to obtain the medicament for treating vitiligo.
7. The process according to claim 6, wherein the temperature of the concentration under reduced pressure is 50 to 70 ℃.
8. The preparation process of claim 6, wherein in the decoction step, the ratio of the Chinese herbal medicine materials to the water is 1 (4-5).
9. The process of claim 6, wherein the stirring step is preceded by the step of sonicating the mixture of extract, iron powder and butter at a temperature of 60-70 ℃ for 10-20 minutes and then stirring.
10. The process of claim 9, wherein the sonication is performed at a power of 60-80W.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110982724.0A CN113476476A (en) | 2021-08-25 | 2021-08-25 | Medicine for treating leukoderma and its preparing process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110982724.0A CN113476476A (en) | 2021-08-25 | 2021-08-25 | Medicine for treating leukoderma and its preparing process |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113476476A true CN113476476A (en) | 2021-10-08 |
Family
ID=77947126
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110982724.0A Pending CN113476476A (en) | 2021-08-25 | 2021-08-25 | Medicine for treating leukoderma and its preparing process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113476476A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101711804A (en) * | 2009-12-01 | 2010-05-26 | 何江思 | Traditional Chinese medicine paste for treating leukoderma diseases |
| CN102131771A (en) * | 2008-04-14 | 2011-07-20 | 阿迪生物科学公司 | Compositions and methods for preparing and using same |
| WO2011136159A1 (en) * | 2010-04-28 | 2011-11-03 | 日本薬品株式会社 | Composition for the treatment of aesthenopia |
| CN106038806A (en) * | 2016-07-11 | 2016-10-26 | 闫秉政 | Traditional Chinese medicine composition for treating leucoderma and preparation method thereof |
| US20190060252A1 (en) * | 2017-08-28 | 2019-02-28 | Axim Biotechnologies, Inc. | Method to treat vitiligo |
| CN110960039A (en) * | 2019-12-03 | 2020-04-07 | 内蒙古蒙医药工程技术研究院 | Buckwheat leaf pillow for improving sleep and calming nerves and manufacturing method thereof |
-
2021
- 2021-08-25 CN CN202110982724.0A patent/CN113476476A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102131771A (en) * | 2008-04-14 | 2011-07-20 | 阿迪生物科学公司 | Compositions and methods for preparing and using same |
| CN101711804A (en) * | 2009-12-01 | 2010-05-26 | 何江思 | Traditional Chinese medicine paste for treating leukoderma diseases |
| WO2011136159A1 (en) * | 2010-04-28 | 2011-11-03 | 日本薬品株式会社 | Composition for the treatment of aesthenopia |
| CN106038806A (en) * | 2016-07-11 | 2016-10-26 | 闫秉政 | Traditional Chinese medicine composition for treating leucoderma and preparation method thereof |
| US20190060252A1 (en) * | 2017-08-28 | 2019-02-28 | Axim Biotechnologies, Inc. | Method to treat vitiligo |
| CN110960039A (en) * | 2019-12-03 | 2020-04-07 | 内蒙古蒙医药工程技术研究院 | Buckwheat leaf pillow for improving sleep and calming nerves and manufacturing method thereof |
Non-Patent Citations (6)
| Title |
|---|
| 卫生部: "《中药新药临床研究指导原则》", 31 December 1993 * |
| 夏木西努尔？肖盖提等: "白癜风的药物治疗现状", 《中国民族医药杂志》 * |
| 张春艳等: "治疗白癜风的中药外用制剂总结分析", 《中华中医药学刊》 * |
| 王光宇、王义新: "《320种中药及其微量元素》", 30 June 2018 * |
| 谢子龙: "《药店店员基础训练手册》", 30 April 2013 * |
| 邵林: "《中药临方炮制技巧》", 31 October 2019 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109331095B (en) | Composition for eliminating eczema and preparation method thereof | |
| CN105213284A (en) | A kind of anti-acne moisturiser and preparation method thereof | |
| US9993510B2 (en) | Acne-removing traditional chinese medicine composition and preparation method thereof | |
| CN113018238A (en) | Anti-bacterial, anti-inflammatory, refreshing and skin-benefiting acne-removing gel and preparation method thereof | |
| CN111821355A (en) | Eyesight-protecting lycium ruthenicum and lutein chewable tablet and preparation method thereof | |
| CN106511211B (en) | Anti-inflammatory acne-removing skin-care lotion and preparation method thereof | |
| CN110934294A (en) | Composition with weight-losing and beauty-maintaining effects and preparation method thereof | |
| CN113509426A (en) | Plant extract compound capable of repairing striae gravidarum and striae adiposity and preparation method and application thereof | |
| CN105125467A (en) | Emulsion removing red blood and preparing method of emulsion | |
| CN105902475B (en) | A kind of rose egg white mask and preparation method thereof | |
| CN114983902B (en) | Skin care composition containing pseudo-ginseng and preparation method thereof | |
| CN113476476A (en) | Medicine for treating leukoderma and its preparing process | |
| CN105213285A (en) | A kind of anti-acne facial cleanser and preparation method thereof | |
| CN109010520A (en) | A kind of ointment and preparation method thereof for treating dark sore | |
| CN111544325A (en) | Herbal collagen anti-chlorine skin care essence and preparation method thereof | |
| CN107822979B (en) | Preparation method of freeze-dried powder of composition with acne removing effect | |
| CN107875059B (en) | Composition with acne removing effect | |
| CN110812377A (en) | Acne treatment and repair composition and application thereof | |
| CN110038076A (en) | A kind of anti-inflammatory analgetic treatment wound compound ganoderma spore powder, preparation method thereof | |
| CN114053329B (en) | Application of broussonetia papyrifera polysaccharide in preparation of medicines or sunscreen cosmetics for preventing and treating ultraviolet injury | |
| CN116474052B (en) | Essential oil for scraping massage and preparation method thereof | |
| CN102948663A (en) | Rana japonica oil granules and preparation method thereof | |
| CN114209785A (en) | Medicine for treating cerebrovascular disease and preparation method thereof | |
| JP2004359674A (en) | Kit for body weight reduction | |
| KR20170124249A (en) | tonic tea |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211008 |